Here are relevant reports on : minimal-residual-disease-mrd-market
-
Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028
The global cardiac marker testing market, valued at US$4.1 billion in 2022, stood at US$4.4 billion in 2023 and is projected to advance at a resilient CAGR of 9.4% from 2023 to 2028, culminating in a forecasted valuation of US$6.9 billion by the end of the period. Increase in chronic heart conditions and aging population, increasing research & funding initiatives from organizations and worldwide rise in prevalence of cardiovascular diseases are a few drivers that collectively contribute to the growth of this market.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022
The Parkinson's disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%. The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinson’s disease and government funding for research. Some of the major players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
- Published: October 2017
- Price: $ 4950
- TOC Available:
-
Stomach Cancer Treatment Market by Treatment, Type (Chemotherapy, Immunotherapy), Disease Indication (Gastric Cancer), Route of Administration, Drug Class (PD-1/PD-L1 inhibitors, HER2 antagonists), Distribution Channel - Global Forecast to 2027
The global stomach cancer treatment market is projected to reach USD 8 billion by 2027 from USD 4 Billion in 2022, at a CAGR of 14% during the forecast period
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Europe Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Europe biomarkers Market, valued at US$16.40 billion in 2024, stood at US$17.46 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of US$28.11 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecast to 2026
The global prostate health market growth is primed to transition from USD 31.8 billion in 2021 to USD 48.9 billion by 2026, showcasing a strong CAGR of 9.0%. Growth in this market is primarily driven by the increasing prevalence of benign prostatic hyperplasia, increasing obesity, investments, funds, and grants for research in prostate health, an increase in the prevalence of prostate cancer, a surge in demand for hormone therapy drugs, emerging therapies for prostate cancer, and an increasing incidence of prostatitis.
- Published: December 2021
- Price: $ 4950
- TOC Available:
-
Sexually Transmitted Diseases Diagnostics Market by Disease Type (CT/NG, Gonorrhea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS, HPV), End User (Laboratory, PoC) and Geography - Global Forecast to 2027
The STDs diagnostics market size is projected to reach $99,431.6 million by 2027 from $91,441.5 million in 2022, at a CAGR of 5.6% during the forecast period. Sexually transmitted diseases diagnostics market is driven by factors such as global prevalence of HIV, CT/NG, and other STDs and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028
The global antibody drug conjugates market, valued at US$7.6 billion in 2022, stood at US$9.7 billion in 2023 and is projected to advance at a resilient CAGR of 15.2% from 2025 to 2028, culminating in a forecasted valuation of US$19.8 billion by the end of the period. Growth in the market can be attributed to various factors such as including the growing prevalence of cancer, and increasing R&D activities for the development of novel ADCs by key market players.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030
The global veterinary biologics market, valued at US$2.61 billion in 2024, stood at US$2.72 billion in 2025 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2030, culminating in a forecasted valuation of US$3.51 billion by the end of the period. The market growth is fueled by increasing demand for effective animal therapeutics, rising populations of livestock and companion animals, and greater awareness of animal health and disease prevention.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics)-Forecast to 2030
The predictive clinical biomarkers market, valued at US$7.84 billion in 2024, stood at US$8.49 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$14.69 billion by the end of the period. he market for predictive clinical biomarkers is growing rapidly as the healthcare industry shifts toward personalized and predictive medicine.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
North America Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)-Forecast to 2030
The North America biomarkers Market, valued at US$23.35 billion in 2024, stood at US$25.13 billion in 2025 and is projected to advance at a resilient CAGR of 11.0% from 2025 to 2030, culminating in a forecasted valuation of US$45.25 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response.
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
